{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T02:01:44Z","timestamp":1794103304105,"version":"4.8.0"},"reference-count":26,"publisher":"American Association for Cancer Research (AACR)","issue":"2","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014535","name":"Center for Individualized Medicine, Mayo Clinic","doi-asserted-by":"crossref","award":["CIM01"],"award-info":[{"award-number":["CIM01"]}],"id":[{"id":"10.13039\/100014535","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Desert Mountain CARE Foundation"},{"name":"David and Twila Woods Foundation"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Data from germline testing in unselected patients with hepatobiliary cancers are limited. Identification of germline predisposition can have important implications on cancer treatment and family counseling. To determine prevalence of pathogenic germline variants (PGV) in patients with hepatobiliary cancer, we undertook a prospective multi-site study of germline sequencing using a &amp;gt;80-gene next-generation sequencing platform among patients with hepatobiliary cancers receiving care at Mayo Clinic Cancer Centers between April 1, 2018 and March 31, 2020. Patients were not selected on the basis of stage, family cancer history, ethnicity, or age. Family cascade testing was offered at no cost. Of 205 patients, the median age was 65 years, 58.5% were male, 81% were White, and 64.4% had cholangiocarcinoma, 21.5% hepatocellular carcinoma, 7.8% gallbladder cancer, and 4.3% carcinoma of ampulla of Vater. PGV were found in 15.6% (n = 32) of patients, including 23 (71%) in moderate and high penetrance cancer susceptibility genes. A total of 75% of patients with a positive result would not have been detected using guidelines for genetic evaluation. Prevalence of PGV was 15.7% in intrahepatic cholangiocarcinoma, 17% in extrahepatic cholangiocarcinoma, 15.9% in hepatocellular cancer, and 33% in carcinoma of ampulla of Vater. On the basis of these genetic findings, 55% were potentially eligible for approved precision therapy and\/or clinical treatment trials. Universal multi-gene panel testing in hepatobiliary cancers was associated with detection of heritable mutations in over 15% of patients most of whom would not have been tested using current guidelines. Germline testing should be considered in all patients with hepatobiliary cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Prevention Relevance:<\/jats:title>\n                    <jats:p>Universal multi-gene testing in hepatobiliary cancers was associated with heritable mutations in over 15% of patients, most of whom would not have been tested using current guidelines. 55% were potentially eligible for approved precision therapy and\/or clinical treatment trials. Germline testing should be considered in all patients with hepatobiliary cancers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/1940-6207.capr-21-0189","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T16:30:16Z","timestamp":1636993816000},"page":"121-128","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Germline Cancer Susceptibility Gene Testing in Unselected Patients with Hepatobiliary Cancers: A Multi-Center Prospective Study"],"prefix":"10.1158","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6122-1374","authenticated-orcid":false,"given":"Pedro LS","family":"Uson Junior","sequence":"first","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6850-6823","authenticated-orcid":false,"given":"Katie L.","family":"Kunze","sequence":"additional","affiliation":[{"name":"2Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7666-7782","authenticated-orcid":false,"given":"Michael A.","family":"Golafshar","sequence":"additional","affiliation":[{"name":"2Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Riegert-Johnson","sequence":"additional","affiliation":[{"name":"3Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Jacksonville, Florida."},{"name":"4Department of Clinical Genomics, Mayo Clinic, Phoenix, Arizona."},{"name":"5Center for Individualized Medicine, Mayo Clinic, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1330-2054","authenticated-orcid":false,"given":"Lisa","family":"Boardman","sequence":"additional","affiliation":[{"name":"6Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh J.","family":"Borad","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ahn","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad B.","family":"Sonbol","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas O.","family":"Faigel","sequence":"additional","affiliation":[{"name":"7Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1671-7519","authenticated-orcid":false,"given":"Norio","family":"Fukami","sequence":"additional","affiliation":[{"name":"7Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Pannala","sequence":"additional","affiliation":[{"name":"7Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3125-7082","authenticated-orcid":false,"given":"Kathleen","family":"Barrus","sequence":"additional","affiliation":[{"name":"4Department of Clinical Genomics, Mayo Clinic, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Mountjoy","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9205-3756","authenticated-orcid":false,"given":"Edward D.","family":"Esplin","sequence":"additional","affiliation":[{"name":"8Invitae, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Nussbaum","sequence":"additional","affiliation":[{"name":"8Invitae, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Keith","family":"Stewart","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona."},{"name":"4Department of Clinical Genomics, Mayo Clinic, Phoenix, Arizona."},{"name":"5Center for Individualized Medicine, Mayo Clinic, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanios","family":"Bekaii-Saab","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Jewel","family":"Samadder","sequence":"additional","affiliation":[{"name":"4Department of Clinical Genomics, Mayo Clinic, Phoenix, Arizona."},{"name":"5Center for Individualized Medicine, Mayo Clinic, Phoenix, Arizona."},{"name":"7Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2021,11,15]]},"reference":[{"key":"2025112418141011800_bib1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.6004\/jnccn.2019.0019","article-title":"Guidelines Insights: Hepatobiliary Cancers, Version 2.2019","volume":"17","author":"Benson","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"2025112418141011800_bib2","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"2025112418141011800_bib3","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"key":"2025112418141011800_bib4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","article-title":"Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma","volume":"71","author":"Bertuccio","year":"2019","journal-title":"J Hepatol"},{"key":"2025112418141011800_bib5","article-title":"Germline testing in biliary tract cancers"},{"key":"2025112418141011800_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.4_suppl.236","article-title":"Landscape of germline mutations in hepatobiliary carcinoma: unrealized risk, untapped clinical trial opportunities","volume":"37","author":"Samadder","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025112418141011800_bib7","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1002\/cncr.32740","article-title":"Germline alterations in patients with biliary tract cancers: a spectrum of significant and previously underappreciated findings","volume":"126","author":"Maynard","year":"2020","journal-title":"Cancer"},{"key":"2025112418141011800_bib8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21037\/cco.2020.02.02","article-title":"Biliary tract cancer and genomic alterations in homologous recombinant deficiency: exploiting synthetic lethality with PARP inhibitors","volume":"9","author":"Ahn","year":"2020","journal-title":"Chin Clin Oncol"},{"key":"2025112418141011800_bib9","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2016-0415","article-title":"Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma: a multicenter retrospective study","volume":"22","author":"Golan","year":"2017","journal-title":"Oncologist"},{"key":"2025112418141011800_bib10","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/cncr.31951","article-title":"Ampullary cancer: evaluation of somatic and germline genetic alterations and association with clinical outcomes","volume":"125","author":"Wong","year":"2019","journal-title":"Cancer"},{"key":"2025112418141011800_bib11","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","article-title":"Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome","volume":"7","author":"Samadder","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025112418141011800_bib12","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.18632\/oncotarget.27224","article-title":"Germline mutations in cancer-predisposition genes in patients with biliary tract cancer","volume":"10","author":"Terashima","year":"2019","journal-title":"Oncotarget"},{"key":"2025112418141011800_bib13","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2018.01.009","article-title":"Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations","volume":"68","author":"Wardell","year":"2018","journal-title":"J Hepatol"},{"key":"2025112418141011800_bib14","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/jnci\/djy024","article-title":"Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms","volume":"110","author":"Lowery","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"2025112418141011800_bib15","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/hep.27969","article-title":"World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma","volume":"62","author":"de Martel","year":"2015","journal-title":"Hepatology"},{"key":"2025112418141011800_bib16","doi-asserted-by":"crossref","first-page":"e107177","DOI":"10.1371\/journal.pone.0107177","article-title":"Large variations in risk of hepatocellular carcinoma and mortality in treatment na\u00efve hepatitis B patients: systematic review with meta-analyses","volume":"9","author":"Thiele","year":"2014","journal-title":"PLoS One"},{"key":"2025112418141011800_bib17","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"key":"2025112418141011800_bib18","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","article-title":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma","volume":"169","author":"Ally","year":"2017","journal-title":"Cell."},{"key":"2025112418141011800_bib19","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1053\/j.gastro.2015.05.061","article-title":"Genetic landscape and biomarkers of hepatocellular carcinoma","volume":"149","author":"Zucman-Rossi","year":"2015","journal-title":"Gastroenterology"},{"key":"2025112418141011800_bib20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41525-019-0096-5","article-title":"Impact of free cancer predisposition cascade genetic testing on uptake in Singapore","volume":"4","author":"Courtney","year":"2019","journal-title":"NPJ Genom Med"},{"key":"2025112418141011800_bib21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ygyno.2019.11.005","article-title":"Low rates of cascade genetic testing among families with hereditary gynecologic cancer: an opportunity to improve cancer prevention","volume":"156","author":"Griffin","year":"2020","journal-title":"Gynecol Oncol"},{"key":"2025112418141011800_bib22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cgh.2007.12.014","article-title":"Sharing genetic test results in Lynch syndrome: communication with close and distant relatives","volume":"6","author":"Stoffel","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025112418141011800_bib23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/jnci\/djy147","article-title":"Cascade genetic testing of relatives for hereditary cancer risk: results of an online initiative","volume":"111","author":"Caswell-Jin","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2025112418141011800_bib24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1089\/gtmb.2012.0381","article-title":"A statewide survey of practitioners to assess knowledge and clinical practices regarding hereditary breast and ovarian cancer","volume":"17","author":"Pal","year":"2013","journal-title":"Genet Test Mol Biomarkers"},{"key":"2025112418141011800_bib25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaoncol.2016.5652","article-title":"Second opinions from medical oncologists for early-stage breast cancer: prevalence, correlates, and consequences","volume":"3","author":"Kurian","year":"2017","journal-title":"JAMA Oncol"},{"key":"2025112418141011800_bib26","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1200\/JCO.2016.71.6480","article-title":"Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer","volume":"35","author":"Kurian","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Cancer Prevention Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/15\/2\/121\/3223422\/121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/15\/2\/121\/3223422\/121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T23:14:24Z","timestamp":1764026064000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article\/15\/2\/121\/678447\/Germline-Cancer-Susceptibility-Gene-Testing-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,15]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,11,15]]},"published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1940-6207.capr-21-0189","relation":{},"ISSN":["1940-6207","1940-6215"],"issn-type":[{"value":"1940-6207","type":"print"},{"value":"1940-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,15]]}}}